This promotional website is for UK healthcare professionals involved in the care of patients with cancer. Adverse event reporting information can be found below.
VENCLYXTO® in Acute Myeloid Leukaemia (AML)
Indicated in combination with a hypomethylating agent or low-dose cytarabine for the treatment of adult patients with newly diagnosed AML who are ineligible for intensive chemotherapy1
Explore Venclyxto data and resources
View on-demand content
View and download resources
Fill in a form to make an appointment with a representative
VENCLYXTO® in Acute Myeloid Leukaemia (AML)
Indicated in combination with a hypomethylating agent or low-dose cytarabine for the treatment of adult patients with newly diagnosed AML who are ineligible for intensive chemotherapy1
Explore Venclyxto data and resources
View on-demand content
View and download resources
Fill in a form to make an appointment with a representative
You are advised to read the Prescribing Information and SmPC to evaluate patient suitability for VENCLYXTO. Click here for SmPC and here for Prescribing Information.
By clicking the link above you will leave the AbbVie Pro website and be taken to the eMC PI portal website.
References
- VENCLYXTO Summary of Product Characteristics.
Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk or via the MHRA Yellow Card app, available in the Google Play or Apple App Stores.
Adverse events should also be reported to AbbVie on GBPV@abbvie.com
UK-VNCAML-240186. Date of preparation: November 2024.
